110 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
occurred or is reasonably expected to occur, (C) the fair market value of the assets under each Plan exceeds the present value of all benefits accrued under … to reflect the relative benefits received by the Company and by the Underwriters from the Offering or, if such allocation is not permitted by applicable law
424B5
SLNO
Soleno Therapeutics Inc
6 May 24
Prospectus supplement for primary offering
4:58pm
-U.S. Holder’s entitlement to benefits under that treaty. Such form must be provided prior to the payment of dividends and must be updated periodically
424B5
SLNO
Soleno Therapeutics Inc
2 May 24
Prospectus supplement for primary offering
4:04pm
appropriate form, certifying the Non-U.S. Holder’s entitlement to benefits under that treaty. Such form must be provided prior to the payment of dividends
8-K
EX-10.1
bxb9 86wu32k95j
30 Jan 24
Departure of Directors or Certain Officers
4:57pm
S-3ASR
EX-5.1
slvrp61w69n ww7tkh
2 Jan 24
Automatic shelf registration
4:06pm
S-3ASR
EX-4.3
dx75ki1r
2 Jan 24
Automatic shelf registration
4:06pm
8-K
EX-10.1
wskf1
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.2
ceprhgb2bp k3eupvig
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.1
2pz y1x57
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
mum6o0i6
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
r50 72v9gf
27 Sep 23
Prospectus supplement for primary offering
5:26pm